NCT07255911 Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS
| NCT ID | NCT07255911 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mst.Sumyara Khatun |
| Condition | PCOS |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2025-02-07 |
| Primary Completion | 2026-01-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2025-02-07 with a primary completion date of 2026-01-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Does combined Cabergoline and letrozole increase ovulation rate What medical problems do participants have when taking drug Cabergoline and Letrozole ? Researchers will compare drug combination of Cabergoline and letrozole to letrozole alone to see combined cabergoline and letrozole works better as ovulation induction. Participants will: experimental group will receive Cabergoline and Letrozole comparator group will receive letrozole alone TVS Monitoring will be done for 3 cycle for ovarian response
Eligibility Criteria
Inclusion Criteria: 1. PCOS patients diagnosed according to Rotterdam criteria. 2. Age: 18-35 years. 3. Primary or secondary subfertility. 4. Selected for ovulation induction. Exclusion Criteria: 1. Women suffered from PCOS like symptom ex. Late onset congenital adrenal hyperplasia, Cushing syndrome. 2. Serum prolactin (more than 50 ng/ml) (Kyritsi et al., 2018). 3. Male factor infertility. 4. Women with other infertility factors (endometriosis, PID,uterine \& tubal causes of infertility). 5. Uncontrolled Medical disease (DM, HTN, kidney disease, liver disease). 6. History of hypersensitivity to cabergoline \& letrozole. 7. Thyroid dysfunction ( serum TSH ≥5mIU/L) 8. BMI:\< 18.5 kg/m2 and ≥30 kg/m2. 9. Patients on metformin therapy. 10. Patient on antiemetic like Domperidone metoclopramide, antipsychotic drug like haloperidol and risperidone, tricyclic antidepressant like amitriptyline, clomipramine, antihypertensive like verapamil, methyldopa, reserpine.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07255911 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying PCOS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07255911 currently recruiting?
Yes, NCT07255911 is actively recruiting participants. Contact the research team at sumirmc09@gmail.com for enrollment information.
Where is the NCT07255911 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh.
Who is sponsoring the NCT07255911 clinical trial?
NCT07255911 is sponsored by Mst.Sumyara Khatun. The trial plans to enroll 72 participants.